DE60221987T2 - Le-zellen (liver engrafting cells), assays und verwendungen davon - Google Patents

Le-zellen (liver engrafting cells), assays und verwendungen davon Download PDF

Info

Publication number
DE60221987T2
DE60221987T2 DE60221987T DE60221987T DE60221987T2 DE 60221987 T2 DE60221987 T2 DE 60221987T2 DE 60221987 T DE60221987 T DE 60221987T DE 60221987 T DE60221987 T DE 60221987T DE 60221987 T2 DE60221987 T2 DE 60221987T2
Authority
DE
Germany
Prior art keywords
cells
liver
composition
cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60221987T
Other languages
German (de)
English (en)
Other versions
DE60221987D1 (de
Inventor
Eric Portola Valley LAGASSE
Timothy Morgan Hill AUSTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbot Medical Inc
Original Assignee
StemCells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23159503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60221987(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by StemCells Inc filed Critical StemCells Inc
Application granted granted Critical
Publication of DE60221987D1 publication Critical patent/DE60221987D1/de
Publication of DE60221987T2 publication Critical patent/DE60221987T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
DE60221987T 2001-06-22 2002-06-21 Le-zellen (liver engrafting cells), assays und verwendungen davon Expired - Lifetime DE60221987T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30053501P 2001-06-22 2001-06-22
US300535P 2001-06-22
PCT/US2002/019646 WO2003000848A2 (en) 2001-06-22 2002-06-21 Liver engrafting cells, assays, and uses thereof

Publications (2)

Publication Number Publication Date
DE60221987D1 DE60221987D1 (de) 2007-10-04
DE60221987T2 true DE60221987T2 (de) 2008-05-15

Family

ID=23159503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221987T Expired - Lifetime DE60221987T2 (de) 2001-06-22 2002-06-21 Le-zellen (liver engrafting cells), assays und verwendungen davon

Country Status (11)

Country Link
US (3) US7211404B2 (enExample)
EP (3) EP1406998B1 (enExample)
JP (2) JP4455876B2 (enExample)
CN (2) CN101974480A (enExample)
AT (1) ATE371018T1 (enExample)
AU (1) AU2002315392B2 (enExample)
CA (1) CA2451637C (enExample)
DE (1) DE60221987T2 (enExample)
DK (1) DK1406998T3 (enExample)
ES (1) ES2292772T3 (enExample)
WO (1) WO2003000848A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
US7211404B2 (en) 2001-06-22 2007-05-01 Stem Cells, Inc. Liver engrafting cells, assays, and uses thereof
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
JP2005511754A (ja) * 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050014217A1 (en) * 2003-07-18 2005-01-20 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
ATE461448T1 (de) * 2004-08-20 2010-04-15 Sekisui Medical Co Ltd Verfahren zur abschätzung des metabolismus eines arzneistoffs in der menschlichen leber sowie der leberfunktion
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
ATE498005T1 (de) 2005-12-21 2011-02-15 Univ Catholique Louvain Isolierte leberstammzellen
EP1998785A4 (en) * 2006-02-21 2009-06-17 Univ Michigan TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2158321B1 (en) * 2007-06-05 2021-08-04 Oregon Health & Science University Method of expanding human hepatocytes in vivo
CN102083967B (zh) * 2007-07-20 2013-05-15 塞拉提斯股份公司 经由定型内胚层(DE-hep)衍生自人胚泡衍生干细胞的新肝细胞群体
US8241898B2 (en) * 2007-12-10 2012-08-14 The Board Of Trustees Of The Leland Stanford Junior University Regenerative dot cells
WO2009111778A2 (en) * 2008-03-07 2009-09-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Lymph nodes as a site for regeneration
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20100227393A1 (en) * 2009-03-06 2010-09-09 Eric Lagasse Liver stem cells: isolation of hepatic progenitor cells from the human gall bladder
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20130071365A1 (en) * 2010-02-16 2013-03-21 Kyushu University, National University Corporation Induced hepatocytes
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
DK3016665T3 (da) 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
JP6672603B2 (ja) * 2015-03-27 2020-03-25 株式会社豊田中央研究所 物質と細胞との間の作用の評価方法
IL256342B2 (en) * 2015-06-23 2023-04-01 Jackson Lab A humanized nsg mouse model with hla-mismatched patient-derived grafts
MX2019009367A (es) * 2017-02-17 2019-10-24 Univ Pittsburgh Commonwealth Sys Higher Education Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneración de tejidos, organogénesis y función para múltiples tejidos.
WO2019210279A1 (en) * 2018-04-27 2019-10-31 The Regents Of The University Of California De novo formation of the biliary system by hepatocyte transdifferentiation
KR20230011948A (ko) * 2020-04-17 2023-01-25 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 향상된 기능을 갖는 면역 세포
WO2023060186A1 (en) * 2021-10-07 2023-04-13 Hepatx Corporation Methods of tracking donor cells in a recipient
JPWO2023132371A1 (enExample) 2022-01-07 2023-07-13

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
AU667680B2 (en) * 1991-08-07 1996-04-04 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
US6069005A (en) * 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
PT671923E (pt) * 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
ATE318075T1 (de) * 1993-11-19 2006-03-15 Einstein Coll Med Hepatoblasten und verfahren zu ihrer isolierung
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1996039489A1 (en) 1995-06-06 1996-12-12 Whitehead Institute For Biomedical Research Isolation of mammalian hematopoietic stem cells
AU6223296A (en) * 1995-06-07 1996-12-30 Novartis Ag Methods for obtaining compositions enriched for hematopoieti c stem cells and antibodies for use therein
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
WO1998017684A2 (en) * 1996-10-25 1998-04-30 Advanced Research & Technology Institute Dna sequences encoding fusions of dna repair proteins and uses thereof
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
AU780256B2 (en) 1999-02-12 2005-03-10 Boco Silicon Valley, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP2004510432A (ja) 2000-10-03 2004-04-08 ユニバーシティ　オブ　ノース　カロライナ 両能性肝前駆細胞の単離方法
WO2002088332A1 (en) * 2001-04-24 2002-11-07 Hokkaido Technology Licensing Office Co.,Ltd. Small liver cell-rich colony, method of preparing the same, method of maturing the same into liver tissue and method of estimating drug function using the matured small liver cell-rich colony
US7211404B2 (en) 2001-06-22 2007-05-01 Stem Cells, Inc. Liver engrafting cells, assays, and uses thereof
US8707400B2 (en) 2007-01-22 2014-04-22 Apple Inc. System and method for implementing an extended authentication and authorization credential store

Also Published As

Publication number Publication date
JP2009183299A (ja) 2009-08-20
US8283164B2 (en) 2012-10-09
EP1956078A3 (en) 2008-10-29
EP1956078A2 (en) 2008-08-13
EP1406998A2 (en) 2004-04-14
CA2451637C (en) 2013-04-23
EP2388330A1 (en) 2011-11-23
JP2004531270A (ja) 2004-10-14
ES2292772T3 (es) 2008-03-16
US7811818B2 (en) 2010-10-12
US20070036774A1 (en) 2007-02-15
EP2388330B1 (en) 2015-05-20
US7211404B2 (en) 2007-05-01
CN1665920A (zh) 2005-09-07
AU2002315392A2 (en) 2003-01-08
ATE371018T1 (de) 2007-09-15
CA2451637A1 (en) 2003-01-03
WO2003000848A3 (en) 2003-03-20
US20110256625A1 (en) 2011-10-20
JP4455876B2 (ja) 2010-04-21
EP1406998B1 (en) 2007-08-22
AU2002315392B2 (en) 2008-01-24
CN101974480A (zh) 2011-02-16
EP1406998A4 (en) 2005-01-19
US20030032184A1 (en) 2003-02-13
DE60221987D1 (de) 2007-10-04
WO2003000848A2 (en) 2003-01-03
DK1406998T3 (da) 2007-12-27

Similar Documents

Publication Publication Date Title
US7211404B2 (en) Liver engrafting cells, assays, and uses thereof
AU2002315392A1 (en) Liver engrafting cells, assays, and uses thereof
Richards et al. Directed growth of early cortical axons is influenced by a chemoattractant released from an intermediate target
Higashiyama et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice
Jarjour et al. Netrin-1 is a chemorepellent for oligodendrocyte precursor cells in the embryonic spinal cord
Al-Lamki et al. Human organ culture: updating the approach to bridge the gap from in vitro to in vivo in inflammation, cancer, and stem cell biology
Abe et al. Transplanted BM and BM side population cells contribute progeny to the lung and liver in irradiated mice
Corti et al. Chemotactic factors enhance myogenic cell migration across an endothelial monolayer
DE69935999T2 (de) Methoden zur introduktion heterologer zellen in fische
DE69434637T2 (de) Hepatoblasten und verfahren zu ihrer isolierung
EP2864474B1 (de) Verfahren zur herstellung von funktionalem fusionsgewebe
Tremblay et al. In vitro colony assays for characterizing tri-potent progenitor cells isolated from the adult murine pancreas
WO2001071016A1 (en) Pluripotential stem cells
Abe et al. Lung cells transplanted to irradiated recipients generate lymphohematopoietic progeny
Li et al. Identification and location of label retaining cells in mouse liver
DE69927685T2 (de) Verfahren zum screenen von verbindungen mit bioaktivität in organgeweben
HK1120563A (en) Liver engrafting cells, assays, and uses thereof
AU2008201806A1 (en) Liver engrafting cells, assays, and uses thereof
Belaaloui et al. Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1)
DE102004025080B4 (de) Multizelluläre Testsysteme
WO2005114178A1 (de) Multizelluläre testsysteme
Preuß et al. A novel agarose-free, standardized generation and versatile ECM characterization of decellularized scaffolds from normal and fibrotic human lung tissue
Colonne et al. Identification and analysis of mouse erythroid progenitor cells
Ghosh et al. Quantitative Study of In Vivo Angiogenesis and Vasculogenesis Using Matrigel-Based Assays

Legal Events

Date Code Title Description
8364 No opposition during term of opposition